株探米国株
日本語 英語
エドガーで原本を確認する
0001555280false00015552802025-05-212025-05-21

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 21, 2025
Zoetis Inc.
(Exact name of registrant as specified in its charter)
Delaware 001-35797 46-0696167
(State or other jurisdiction (Commission File (I.R.S. Employer
of incorporation) Number) Identification No.)
10 Sylvan Way,
Parsippany,
New Jersey
07054
(Address of principal executive offices) (Zip Code)

(973) 822-7000
(Registrant's telephone number, including area code)
Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.01 per share ZTS New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

                                     Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐








Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective May 21, 2025, Mr. Robert Scully retired from the Board of Directors of Zoetis Inc. (the “Company”), prior to the Company’s 2025 Annual Meeting of Shareholders (the “Annual Meeting”) in accordance with the Company’s director retirement policy.
Effective May 21, 2025, Dr. Mark Stetter was elected to the Board of Directors of the company at the Annual Meeting. On May 22, 2025, the Company issued a press release announcing the election of Dr. Stetter. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 5.07. Submission of Matters to a Vote of Security Holders.
As discussed under Item 5.02 of this Current Report on Form 8-K, on May 21, 2025, the Company held the Annual Meeting. At the Annual Meeting, the Company’s shareholders voted on four proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 9, 2025 (the “Proxy Statement”). There were 392,890,991 shares of common stock present at the Annual Meeting in person or by proxy, which represented 88.08% of the voting power of the shares of common stock entitled to vote at the Annual Meeting, and which constituted a quorum for the transaction of business. Holders of the Company’s common stock were entitled to one vote for each share held as of the close of business on March 28, 2025 (the “Record Date”).

The shareholders of the Company voted on the following proposals at the Annual Meeting:

1. To elect twelve directors, each to serve for a one-year term until the 2026 Annual Meeting of Shareholders or until each director’s successor has been elected and qualified, or until such director’s earlier death, resignation or removal.
2. A non-binding advisory vote on the compensation program for the Company’s named executive officers as disclosed in the Proxy Statement.
3. To ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
4. To approve a shareholder proposal regarding a special shareholder meeting improvement.
The voting results for each of these proposals are detailed below.
1. Election of Directors
Nominee Votes For Votes Against Abstentions Broker Non-Votes
Paul M. Bisaro 369,537,255 2,013,136 524,266 20,816,334
Vanessa Broadhurst 367,646,157 3,694,456 734,044 20,816,334
Frank A. D'Amelio
350,971,578 20,566,366 536,713 20,816,334
Gavin D.K. Hattersley 367,143,208 4,384,681 546,768 20,816,334
Sanjay Khosla 363,294,340 8,250,547 529,770 20,816,334
Antoinette R. Leatherberry 370,300,160 1,239,724 534,773 20,816,334
Michael B. McCallister
355,271,093 16,276,093 527,471 20,816,334
Gregory Norden 346,322,416 24,910,002 842,239 20,816,334
Louise M. Parent 359,379,090 12,177,746 517,821 20,816,334
Kristin C. Peck 366,830,103 3,876,770 1,367,784 20,816,334
Willie M. Reed 363,493,695 7,857,615 723,347 20,816,334
Mark Stetter 371,157,755 379,799 537,103 20,816,334
Each of the twelve nominees for director was elected to serve for a one-year term until the 2026 Annual Meeting of Shareholders or until each director’s successor has been elected and qualified, or until such director’s earlier death, resignation or removal.
2. Advisory Vote on Executive Compensation
Votes For Votes Against Abstentions Broker Non-Votes
334,181,202 35,190,564 2,702,891 20,816,334



The shareholders approved, on a non-binding advisory basis, the compensation program for the Company’s named executive officers as disclosed in the Proxy Statement.
3. Ratification of Appointment of Independent Registered Public Accounting Firm
Votes For Votes Against Abstentions Broker Non-Votes
384,785,460 7,615,268 490,263
The shareholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
4. Shareholder Proposal
Votes For
Votes Against
Abstentions
Broker Non-Votes
50,420,440 320,662,986 991,231 20,816,334
The shareholders did not approve the shareholder proposal regarding a special shareholder meeting improvement.

Item 9.01. Financial Statements and Exhibits.

(d)    Exhibits
Description
Press Release issued on May 22, 2025, regarding the election of Dr. Mark Stetter.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ZOETIS INC.
Dated: May 22, 2025 By: /s/ Roxanne Lagano
Roxanne Lagano
Executive Vice President,
General Counsel and Corporate Secretary


EX-99.1 2 exhibit991newdirector052125.htm EX-99.1 Document

Exhibit 99.1
image_0.jpg                
Media Contacts:
Investor Contacts:
Jennifer Albano Steve Frank
1-862-399-0810 (o) 1-973-822-7141 (o)
jennifer.albano@zoetis.com steve.frank@zoetis.com
Laura Panza Nick Soonthornchai
1-973-975-5176 (o) 1-973-443-2792 (o)
laura.panza@zoetis.com
nick.soonthornchai@zoetis.com


Dr. Mark Stetter Elected to Zoetis Board of Directors

Dean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board

PARSIPPANY, N.J. – May 22, 2025 – Zoetis Inc. (NYSE: ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company’s annual shareholder meeting on May 21, 2025.

Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to the Zoetis Board. His career in animal health includes pets, livestock, exotic animals, research and wildlife. He will serve on the Board’s Quality and Innovation Committee.

“Dr. Stetter brings invaluable real-world experience in animal health to our Board,” said Kristin Peck, Chief Executive Officer of Zoetis. “Our customers are at the heart of everything we do and leveraging Mark’s experiences and insights will help us continue to adapt and innovate to best serve them. We’re thrilled to have him join our Board as we continue to live our purpose of advancing care for animals.”




“We are pleased to welcome Dr. Mark Stetter to Zoetis’ Board of Directors, and we look forward to the contributions he will make as we continue to advance the animal health industry and deliver innovation to our customers,” said Zoetis Board Chair Michael McCallister.

Dr. Stetter has served as Dean of the University of California, Davis School of Veterinary Medicine since 2021. In this role he oversees all aspects of the school including education, research, veterinary hospitals, animal health diagnostic labs, centers and institutes. He was Dean and Professor at the College of Veterinary Medicine and Biomedical Sciences at Colorado State University from 2012 until 2021. Prior to joining higher education, Dr. Stetter held various roles at The Walt Disney Company, The Bronx Zoo/Wildlife Conservation Society and the Audubon Nature Institute. Dr. Stetter holds a Doctor of Veterinary Medicine and a Bachelor of Science degree in biochemistry and chemistry from the University of Illinois at Champaign-Urbana.

“I am incredibly grateful for the opportunity to join Zoetis’ Board of Directors,” said Dr. Mark Stetter. “As a veterinarian I've seen firsthand the impact the company’s innovative products have on animals, and I look forward to bringing my professional expertise and passion for animal health to Zoetis as they continue to advance care for the industry.”

About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.

ZTS-COR
ZTS-IR
# # #
-2-